Saleem Sofiyan, Zhuang Hean, Biswal Shyam, Christen Yves, Doré Sylvain
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Stroke. 2008 Dec;39(12):3389-96. doi: 10.1161/STROKEAHA.108.523480. Epub 2008 Oct 9.
Ginkgo biloba extracts are now prescribed in several countries for their reported health benefits, particularly for medicinal properties in the brain. The standardized Ginkgo extract, EGb761, has been reported to protect neurons against oxidative stress, but the underlying mechanisms are not fully understood.
To characterize the oral consumption of EGb761 in transient ischemia, we performed the middle cerebral artery occlusion (MCAO) filament model in wild-type and heme oxygenase 1 (HO-1) knockouts. Mice were pretreated for 7 days before the transient occlusion or posttreated acutely during reperfusion; then neurobehavioral scores and infarct volumes were assessed. Furthermore, primary cortical neuronal cultures were used to investigate the contribution of the antioxidant enzyme HO-1 in the EGb761-associated cytoprotection.
Mice that were pretreated with EGb761 had 50.9+/-5.6% less neurological dysfunction and 48.2+/-5.3% smaller infarct volumes than vehicle-treated mice; this effect was abolished in HO-1 knockouts. In addition to the prophylactic properties of EGb761, acute posttreatment 5 minutes and 4.5 hours after reperfusion also led to significant reduction in infarct size (P<0.01). After our previous demonstration that EGb761 significantly induced HO-1 levels in a dose- and time-dependent manner in neuronal cultures, here we revealed that this de novo HO-1 induction was required for neuroprotection against free radical damage and excitotoxicity as it was significantly attenuated by the enzyme inhibitor.
These results demonstrate that EGb761 could be used as a preventive or therapeutic agent in cerebral ischemia and suggest that HO-1 contributes, at least in part, to EGb761 neuroprotection.
银杏叶提取物因其宣称的健康益处,尤其是对大脑的药用特性,目前在多个国家被开出处方。标准化银杏提取物EGb761已被报道可保护神经元免受氧化应激影响,但其潜在机制尚未完全明确。
为了表征EGb761在短暂性脑缺血中的口服效果,我们在野生型和血红素加氧酶1(HO-1)基因敲除小鼠中进行了大脑中动脉闭塞(MCAO)丝线模型实验。小鼠在短暂闭塞前预处理7天,或在再灌注期间进行急性后处理;然后评估神经行为评分和梗死体积。此外,使用原代皮质神经元培养物来研究抗氧化酶HO-1在EGb761相关细胞保护中的作用。
用EGb761预处理的小鼠神经功能障碍比用溶剂处理的小鼠少50.9±5.6%,梗死体积小48.2±5.3%;这种作用在HO-1基因敲除小鼠中消失。除了EGb761的预防特性外,再灌注后5分钟和4.5小时进行急性后处理也导致梗死面积显著减小(P<0.01)。在我们之前证明EGb761在神经元培养物中以剂量和时间依赖性方式显著诱导HO-1水平后,在此我们发现这种新生HO-1诱导对于抵抗自由基损伤和兴奋性毒性的神经保护是必需的,因为它被酶抑制剂显著减弱。
这些结果表明EGb761可作为脑缺血的预防或治疗药物,并提示HO-1至少部分地促成了EGb761的神经保护作用。